Neuphoria Therapeutics (NEUP) Expected to Announce Earnings on Friday

Neuphoria Therapeutics (NASDAQ:NEUP) is projected to post its results before the market opens on Friday, February 13th. Analysts expect Neuphoria Therapeutics to post earnings of ($0.56) per share for the quarter.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($4.41) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, analysts expect Neuphoria Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Neuphoria Therapeutics Stock Performance

Shares of Neuphoria Therapeutics stock opened at $4.05 on Wednesday. Neuphoria Therapeutics has a 1 year low of $3.64 and a 1 year high of $21.40. The firm’s 50-day simple moving average is $4.02 and its 200-day simple moving average is $7.39. The firm has a market cap of $21.79 million, a PE ratio of -0.83 and a beta of 0.52.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Zacks Research upgraded Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Wall Street Zen lowered Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Thursday, January 22nd. Finally, HC Wainwright reduced their price objective on Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, December 5th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $21.00.

Institutional Trading of Neuphoria Therapeutics

An institutional investor recently bought a new position in Neuphoria Therapeutics stock. Millennium Management LLC bought a new position in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 18,329 shares of the company’s stock, valued at approximately $216,000. Millennium Management LLC owned about 0.78% of Neuphoria Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.